Regeneron Pharmaceuticals Buy Hold or Sell Recommendation

REGN -- USA Stock  

USD 286.15  1.09  0.38%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Regeneron Pharmaceuticals is 'Strong Hold'. Macroaxis provides Regeneron Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding REGN positions. The advice algorithm takes into account all of Regeneron Pharmaceuticals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from REGN buy-and-hold prospective. Additionally take a look at Regeneron Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Execute Advice
Sell Regeneron PharmaceuticalsBuy Regeneron Pharmaceuticals
Strong Hold


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon Regeneron Pharmaceuticals has a risk adjusted performance of (0.038636), jensen alpha of (0.13), total risk alpha of (0.16), sortino ratio of 0.0 and treynor ratio of (0.1)
Macroaxis provides advice on Regeneron Pharmaceuticals to complement and cross-verify current analyst consensus on Regeneron Pharmaceuticals. Our recommendation engine determines the corporation potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Regeneron Pharmaceuticals is not overpriced, please check all Regeneron Pharmaceuticals fundamentals including its Debt to Equity, Total Asset and the relationship between EBITDA and Earnings Per Share . Given that Regeneron Pharmaceuticals has Number of Shares Shorted of 2.42M, we recommend you check out Regeneron Pharmaceuticals market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your recent risk tolerance and investing horizon.

Regeneron Pharmaceuticals Trading Alerts and Improvement Suggestions

Regeneron Pharmaceuticals generates negative expected return over the last 30 days
About 73.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Acquisition by Douglas McCorkle of 4562 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Regeneron Pharmaceuticals current analysts recommendations

Target Median Price375.00
Target Mean Price386.33
Recommendation Mean2.50
Target High Price496.00
Number Of Analyst Opinions18
Target Low Price325.00

Regeneron Pharmaceuticals Returns Distribution Density

Mean Return0.09Value At Risk3.26
Potential Upside2.53Standard Deviation1.81
 Return Density 

Regeneron Pharmaceuticals Greeks

Alpha over DOW
Beta against DOW=1.03
Overall volatility
Information ratio =0.07

Regeneron Pharmaceuticals Volatility Alert

Regeneron Pharmaceuticals exhibits very low volatility with skewness of -0.27 and kurtosis of -0.19. However, we advise investors to further study Regeneron Pharmaceuticals technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare Regeneron Pharmaceuticals to competition

Regeneron Pharmaceuticals Fundamental Vs Peers

FundamentalsRegeneron PharmaceuticalsPeer Average
Return On Equity24.43% (0.31)%
Return On Asset11.57% (0.14)%
Profit Margin28.59% (1.27)%
Operating Margin32.08% (5.51)%
Current Valuation28.86B16.62B
Shares Outstanding107.98M571.82M
Shares Owned by Insiders24.61% 10.09%
Shares Owned by Institutions72.68% 39.21%
Number of Shares Shorted2.42M4.71M
Price to Earning15.88X28.72X
Price to Book3.20X9.51X
Price to Sales4.34X11.42X
Gross Profit4.09B27.38B
Net Income2.07B570.98M
Cash and Equivalents2.67B2.7B
Cash per Share24.40X5.01X
Total Debt711.3M5.32B
Debt to Equity7.20% 48.70%
Current Ratio3.88X2.16X
Book Value Per Share89.25X1.93K
Cash Flow from Operations1.12B971.22M
Short Ratio3.37X4.00X
Earnings Per Share18.00X3.12X
Price to Earnings To Growth1.95X4.89X
Number of Employees7.55K18.84K
Market Capitalization31.4B19.03B
Total Asset5.61B29.47B
Retained Earnings677.3M9.33B
Working Capital2.1B1.48B
Current Asset2.92B9.34B
   Acquisition by Douglas McCorkle of 4562 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 [view details]